A detailed history of Capital Analysts, LLC transactions in Argenx Se stock. As of the latest transaction made, Capital Analysts, LLC holds 22 shares of ARGX stock, worth $13,823. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22
Holding current value
$13,823
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$434.22 - $551.9 $9,552 - $12,141
22 New
22 $12,000
Q4 2020

Feb 16, 2021

SELL
$248.13 - $308.36 $676,154 - $840,281
-2,725 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$215.51 - $272.51 $242,448 - $306,573
1,125 Added 70.31%
2,725 $715,000
Q2 2020

Aug 07, 2020

BUY
$127.44 - $232.72 $111,510 - $203,630
875 Added 120.69%
1,600 $360,000
Q4 2019

Feb 12, 2020

BUY
$106.59 - $164.21 $66,618 - $102,631
625 Added 625.0%
725 $116,000
Q3 2019

Nov 12, 2019

BUY
$113.31 - $150.51 $11,331 - $15,051
100 New
100 $11,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Capital Analysts, LLC Portfolio

Follow Capital Analysts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Analysts, LLC with notifications on news.